Equities analysts forecast that Merit Medical Systems, Inc. (NASDAQ:MMSI) will announce sales of $252.28 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Merit Medical Systems’ earnings. The highest sales estimate is $255.80 million and the lowest is $249.09 million. Merit Medical Systems reported sales of $233.25 million during the same quarter last year, which indicates a positive year over year growth rate of 8.2%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 25th.
On average, analysts expect that Merit Medical Systems will report full-year sales of $989.20 million for the current financial year, with estimates ranging from $986.02 million to $992.73 million. For the next fiscal year, analysts anticipate that the business will post sales of $1.05 billion, with estimates ranging from $1.04 billion to $1.06 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Merit Medical Systems.
Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.45 by ($0.17). Merit Medical Systems had a return on equity of 9.23% and a net margin of 1.94%. The company had revenue of $243.05 million for the quarter, compared to analyst estimates of $248.53 million. During the same quarter in the prior year, the firm earned $0.47 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis.
In other Merit Medical Systems news, CFO Raul Jr. Parra purchased 2,525 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was bought at an average cost of $25.50 per share, for a total transaction of $64,387.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Fred P. Lampropoulos sold 150,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $30.72, for a total value of $4,608,000.00. Following the completion of the transaction, the chief executive officer now owns 929,991 shares of the company’s stock, valued at $28,569,323.52. The disclosure for this sale can be found here. Insiders own 4.75% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY grew its stake in shares of Merit Medical Systems by 3.2% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 17,613 shares of the medical instruments supplier’s stock valued at $536,000 after buying an additional 554 shares during the period. Voloridge Investment Management LLC purchased a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $783,000. Granahan Investment Management Inc. MA purchased a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $1,495,000. Barclays PLC grew its stake in shares of Merit Medical Systems by 157.8% during the 3rd quarter. Barclays PLC now owns 56,934 shares of the medical instruments supplier’s stock valued at $1,735,000 after buying an additional 155,384 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Merit Medical Systems by 62.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 207,127 shares of the medical instruments supplier’s stock valued at $6,309,000 after buying an additional 79,366 shares during the period. 97.48% of the stock is owned by institutional investors.
Shares of Merit Medical Systems stock opened at $28.00 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.88 and a quick ratio of 1.47. Merit Medical Systems has a 1 year low of $19.50 and a 1 year high of $64.03. The company has a market capitalization of $1.56 billion, a P/E ratio of 16.57, a P/E/G ratio of 2.37 and a beta of 0.95. The business has a 50 day moving average price of $27.71 and a 200 day moving average price of $40.65.
About Merit Medical Systems
Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.
Further Reading: What is an inverted yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.